We speculated that this may be due to the different AR activity—as PSA levels rise in most of the primary PCa when first diagnosed—this relatively active AR activity would repress ARHGEF2 expression at the transcription level. The gene discussed is ARHGEF2; the disease is posterior cortical atrophy.